The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Metal-based drugs that break the rules
Open accessAbstract
Cisplatin and other platinum compounds have had a huge impact in the treatment of cancer and are applied in the majority of anticancer chemotherapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
New trends for metal complexes with anticancer activity
Bruijnincx, P. C., & Sadler, P. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.11.013 · Cited by 1,306
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Self-citationIn Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Self-citationMetal-based antitumour drugs in the post genomic era
Dyson, P. J., & Sava, G. (2006) · Dalton Transactions · doi:10.1039/b601840h · Cited by 771
Self-citationReview of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Reedijk, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737293100 · Cited by 617
Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400053101 · Cited by 583
Aird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
Apoptotic cell: linkage of inflammation and wound healing
Wu, Y.-S., & Chen, S.-N. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00001 · Cited by 500
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
The development of RAPTA compounds for the treatment of tumors
Murray, B. S., Babak, M. V., Hartinger, C. G., & Dyson, P. J. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.06.014 · Cited by 455
Self-citationMetal complexes of curcumin – synthetic strategies, structures and medicinal applications
Wanninger, S., Lorenz, V., Subhan, A., & Edelmann, F. T. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00088b · Cited by 426
Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., & Rigobello, M. P. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.12.021 · Cited by 415
Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.-T., & Austin, C. P. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001862 · Cited by 401
Ruthenium metallopharmaceuticals
Clarke, M. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00025-5 · Cited by 396
Particular aspects of platinum compounds used at present in cancer treatment
Desoize, B., & Madoulet, C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00219-0 · Cited by 393
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
Leijen, S., Burgers, S. A., Baas, P., Pluim, D., Tibben, M., van Werkhoven, E., Alessio, E., Sava, G., Beijnen, J. H., & Schellens, J. H. M. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0179-1 · Cited by 374
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Verdine, G. L., & Walensky, L. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2184 · Cited by 361
How acute promyelocytic leukaemia revived arsenic
Zhu, J., Chen, Z., Lallemand-Breitenbach, V., & de Thé, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc887 · Cited by 321
Adhireksan, Z., Davey, G. E., Campomanes, P., Groessl, M., Clavel, C. M., Yu, H., Nazarov, A. A., Yeo, C. H. F., Ang, W. H., Dröge, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4462 · Cited by 297
Self-citationTargeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
Zutphen, S. V., & Reedijk, J. (2005) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2005.03.005 · Cited by 295
Mirabelli, C. K., Johnson, R. K., Sung, C. M., Faucette, L. F., Muirhead, K. A., & Crooke, S. T. (1985) · PubMed · Cited by 295
Metalloporphyrin class of therapeutic catalytic antioxidants
Patel, M., & Day, B. J. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01336-x · Cited by 253
Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity
Nowak-Sliwinska, P., van Beijnum, J. R., Casini, A., Nazarov, A. A., Wagnières, G., van den Bergh, H., Dyson, P. J., & Griffioen, A. W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002074 · Cited by 248
Self-citationEnzyme inhibition by metal complexes: concepts, strategies and applications
Kilpin, K. J., & Dyson, P. J. (2013) · Chemical Science · doi:10.1039/c3sc22349c · Cited by 242
Self-citationPlatinum-Induced Filamentous Growth in Escherichia coli
Rosenberg, B., Renshaw, E., Vancamp, L., Hartwick, J., & Drobnik, J. (1967) · Journal of Bacteriology · doi:10.1128/jb.93.2.716-721.1967 · Cited by 212
Meng, X., Leyva, M. L., Jenny, M., Gross, I., Benosman, S., Fricker, B., Harlepp, S., Hébraud, P., Boos, A., Wlosik, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4408 · Cited by 208
Pongratz, M., Schluga, P., Jakupec, M. A., Arion, V. B., Hartinger, C. G., Allmaier, G., & Keppler, B. K. (2004) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b309160k · Cited by 206
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound
Bergamo (1992) · International Journal of Oncology · doi:10.3892/ijo_00000119 · Cited by 202
Coste, F., Malinge, J.-M., Serre, L., Leng, M., Zelwer, C., Shepard, W., & Roth, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.8.1837 · Cited by 199
Ware, D. C., Palmer, B. D., Wilson, W. R., & Denny, W. A. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00065a006 · Cited by 193
Pettinari, R., Marchetti, F., Condello, F., Pettinari, C., Lupidi, G., Scopelliti, R., Mukhopadhyay, S., Riedel, T., & Dyson, P. J. (2014) · Organometallics · doi:10.1021/om500317b · Cited by 187
Self-citationMetal Complexes, their Cellular Targets and Potential for Cancer Therapy
Chen, D., Milacic, V., Frezza, M., & Dou, Q. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787582183 · Cited by 178
A Ruthenium Antimetastasis Agent Forms Specific Histone Protein Adducts in the Nucleosome Core
Wu, B., Ong, M. S., Groessl, M., Adhireksan, Z., Hartinger, C. G., Dyson, P. J., & Davey, C. A. (2011) · Chemistry – A European Journal · doi:10.1002/chem.201100298 · Cited by 174
Self-citationFrom Conventional to Unusual Enzyme Inhibitor Scaffolds: The Quest for Target Specificity
Meggers, E. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201005673 · Cited by 158
Approaches to the design of catalytic metallodrugs
Soldevila‐Barreda, J. J., & Sadler, P. J. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.01.024 · Cited by 152
Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study
Renfrew, A. K., Bryce, N. S., & Hambley, T. W. (2013) · Chemical Science · doi:10.1039/c3sc51530c · Cited by 149
Targeting the Undruggable Proteome: The Small Molecules of My Dreams
Crews, C. M. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.011 · Cited by 147
Ashur, I., Goldschmidt, R., Pinkas, I., Salomon, Y., Szewczyk, G. M., Sarna, T., & Scherz, A. J. (2009) · The Journal of Physical Chemistry A · doi:10.1021/jp900580e · Cited by 145
Cisplatin Resistance and Transcription Factors
Torigoe, T., Izumi, H., Ishiguchi, H., Yoshida, Y., Tanabe, M., Yoshida, T., Igarashi, T., Niina, I., Wakasugi, T., Imaizumi, T., et al. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011053352587 · Cited by 133
Jodrell, D. I., Evans, T. R. J., Steward, W. P., Cameron, D., Prendiville, J., Aschele, C., Noberasco, C., Lind, M., Carmichael, J., Dobbs, N. A., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.032 · Cited by 130
Glutathione S-conjugates as prodrugs to target drug-resistant tumors
Ramsay, E. E., & Dilda, P. J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00181 · Cited by 129
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
Weiss, A., Ding, X., B, J. R. V. B., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M. G., Shen, L., Schlingemann, R. O., et al. (2015) · Angiogenesis · doi:10.1007/s10456-015-9462-9 · Cited by 124
Self-citationGold complexes as prospective metal-based anticancer drugs.
Milacic, V., Fregona, D., & Dou, Q. P. (2008) · PubMed · doi:10.14670/hh-23.101 · Cited by 119
Role of transporters in the distribution of platinum-based drugs
Harrach, S., & Ciarimboli, G. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00085 · Cited by 114
PARK, S.-H. G., LEE, J. G., Berek, J. S., & HU, M. Y. C.-T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2579 · Cited by 106
Mao, J., Zhang, Y., Zhu, J., Zhang, C., & Guo, Z. (2009) · Chemical Communications · doi:10.1039/b817968a · Cited by 106
Billecke, C., Finniss, S., Tahash, L., Miller, C. G., Mikkelsen, T., Farrell, N. P., & Bögler, O. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-004 · Cited by 90
Voltage Gated ion Channels: Targets for Anticonvulsant Drugs
Errington, A. C., Stöhr, T., & Lees, G. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053386872 · Cited by 89
Ahn, G., Botting, K. J., Patterson, A. V., Ware, D. C., Tercel, M., & Wilson, W. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.03.007 · Cited by 81
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy
Weiss, A., Bonvin, D., Berndsen, R. H., Scherrer, E., Wong, T. J., Dyson, P. J., Griffioen, A. W., & Nowak-Sliwinska, P. M. (2015) · Scientific Reports · doi:10.1038/srep08990 · Cited by 71
Self-citationBytzek, A. K., Boeck, K., Hermann, G., et al. (2011) · Metallomics · doi:10.1039/c1mt00055a · Cited by 64
McCollum, G., Keng, P. C., States, J. C., & McCabe, M. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080713 · Cited by 61
A Novel Design Strategy for Stable Metal Complexes of Nitrogen Mustards as Bioreductive Prodrugs
Parker, L. L., Lacy, S. M., Farrugia, L. J., Evans, C., Robins, D. J., O’Hare, C. C., Hartley, J. A., Jaffar, M., & Stratford, I. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049866w · Cited by 60
Ruthenium and Other Non‐Platinum Anticancer Compounds
Bratsos, I., Gianferrara, T., Alessio, E., Hartinger, C. G., Jakupec, M. A., & Keppler, B. K. (2011) · Wiley eBooks · doi:10.1002/9783527633104.ch5 · Cited by 54
Medicinal Inorganic Chemistry: State of the Art, New Trends, and a Vision of the Future
Farrer, N. J., & Sadler, P. J. (2011) · Wiley eBooks · doi:10.1002/9783527633104.ch1 · Cited by 49
Amin, A., & Buratovich, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709790361566 · Cited by 47
O’Connor, A. E., Gee, M. M. M., Likar, Y., Ponomarev, V., Callanan, J. J., O’Shea, D. F., Byrne, A. T., & Gallagher, W. M. (2011) · International Journal of Cancer · doi:10.1002/ijc.26073 · Cited by 44
A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors
Tsimberidou, A. M., Camacho, L. H., Verstovšek, S., Ng, C. S., Hong, D. S., Uehara, C., Gutierrez, C., Daring, S., Stevens, J., Komarnitsky, P. B., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2984 · Cited by 43
Richardson, L. C., Neri, A., Tai, E. W., & Glenn, J. D. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.09.010 · Cited by 43
Apoptotic Response to Photodynamic Therapy versus the Bcl-2 Antagonist HA14-1¶
Kessel, D. H., & Reiners, J. J. (2002) · Photochemistry and Photobiology · doi:10.1562/0031-8655(2002)0760314artptv2.0.co2 · Cited by 37
The Novel Arsenical Darinaparsin Is Transported by Cystine Importing Systems
Garnier, N. M., Redstone, G. G. J., Dahabieh, M. S., Nichol, J. N., Rincon, S. V. D., Gu, Y., Bohle, D. S., Sun, Y., Conklin, D. S., Mann, K. K., et al. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.089433 · Cited by 32
High precision multi-genome scale reannotation of enzyme function by EFICAz
Arakaki, A. K., Tian, W., & Skolnick, J. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-315 · Cited by 30
Tomšík, P., Muthná, D., Řezáčová, M., Mičuda, S., Ćmielová, J., Hroch, M., Endlicher, R., Červinková, Z., Rudolf, E., Hann, S., et al. (2014) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2014.10.050 · Cited by 26
Shingu, T., Chumbalkar, V. C., Gwak, H., Fujiwara, K., Kondo, S., Farrell, N. P., & Bögler, O. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq095 · Cited by 23
Fishel, M. L., Gamcsik, M. P., Delaney, S. M., Zuhowski, E. G., Maher, V. M., Karrison, T. G., Moschel, R. C., Egorin, M. J., & Dolan, M. E. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0901-3 · Cited by 18
Gamberi, T., Magherini, F., Fiaschi, T., Landini, I., Massai, L., Valocchia, E., Bianchi, L., Bini, L., Gabbiani, C., Nobili, S., et al. (2015) · Molecular BioSystems · doi:10.1039/c5mb00008d · Cited by 14
Employing Pancreatic Tumor γ-Glutamyltransferase for Therapeutic Delivery
Ramsay, E. E., Decollogne, S., Joshi, S. M., Corti, A., Apte, M. V., Alfonso Pompella, C., Hogg, P. J., & Dilda, P. J. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400664t · Cited by 13
Cited by
Metal complexes in cancer therapy – an update from drug design perspective
Ndagi, U., Mhlongo, N., & Soliman, M. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s119488 · Cited by 935
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Alessio, E. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600986 · Cited by 388
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Redox‐Active Metal Complexes for Anticancer Therapy
Zhang, P., & Sadler, P. J. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600908 · Cited by 274
Metadata
- Authors
- Allardyce, C. S., & Dyson, P. J.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2016
- Volume
- 45
- Issue
- 8
- Pages
- 3201-3209
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2255424419
- Cited by
- 308
- References
- 77
- FWCI
- 21.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.